DKP 21102
Alternative Names: DKP-21102Latest Information Update: 29 Jun 2023
At a glance
- Originator Dongkwang Pharm
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dyslipidaemias
Most Recent Events
- 19 Apr 2023 Preclinical trials in Dyslipidaemias in South Korea (unspecified route) (before April 2023) (NCT05809687)
- 14 Apr 2023 Dongkwang Pharm plans a phase III trial for Dyslipidemias (unspecified) (NCT05809687)